MedTrace Logo

Application of Low-dose Muscle Relaxants in Bronchoscopic Interventional Procedures

NCT07035301 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2026-03-03

No results posted yet for this study

Summary

The purpose of this clinical trial is to observe the use of low-dose muscle relaxants in bronchoscopy intervention surgeries, compared with no muscle relaxants, in terms of the satisfaction of tracheal tube insertion after anesthesia induction, the incidence of laryngospasm, the grading of intraoperative cough and movement, and the recovery of patients after surgery. The main questions it aims to answer are:

* How safe and feasible is the use of low-dose muscle relaxants in bronchoscopy intervention surgeries?
* Is the muscle relaxant regimen better than the no-muscle-relaxant regimen?

Participants will:

* During anesthesia induction, the experimental group will use low-dose muscle relaxants for anesthesia, while the control group will not use muscle relaxants for anesthesia.
* Record the satisfaction of mask ventilation and the incidence of laryngospasm.

Conditions

  • Disease of Respiratory System

Interventions

DRUG

Normal Saline (Placebo)

During anesthesia induction, an equal volume of normal saline was used instead of rocuronium for anesthesia.

DRUG

Lidocaine Intravenous Infusion

Lidocaine was administered at a dose of 0.5mg/kg for the induction of anesthesia.

DRUG

Remimazolam Tosilate

Remimazolam was administered at a dose of 0.2 mg/kg for the induction of anesthesia.

DRUG

Remifentanil

Remifentanil was administered at a dose of 3 micrograms per kilogram for the induction of anesthesia.

DRUG

Rocuronium (0.15mg/kg/body mass)

Rocuronium was administered at a dose of 0.15mg/kg for the induction of anesthesia.

Sponsors & Collaborators

  • First Affiliated Hospital of Harbin Medical University

    collaborator OTHER

  • Harbin Medical University

    lead OTHER

Principal Investigators

  • SHI Jinghui SHI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-17
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07035301 on ClinicalTrials.gov